+34 620 10 75 37info@nanbiosis.com

Nanbiosis

Diabetes mellitus and pancreatic islet transplant: DRIVE

Today in the World Diabetes Day it is a good moment to remember The Patient Panel of the European project DRIVE- Diabetes Reversing Implants, held in Vitoria (Alava) on June 2 where researches and doctors met with patients and families.

The Panel was organized by the NanoBioCel group of CIBER BBN and NANBIOSIS Unit 10 Drug Formulation, with the purpose of letting know the DRIVE project to patients and concect patients with the project scientists and experts in pancreas and stem cell transplantation. Thus, one of the most important health objectives of the European Union was met: to promote direct access for patients and families, in this case patients with diabetes mellitus, to information on the cutting-edge research being carried out at European level on this disease in order to empower them, so that they are aware of their rights and responsibilities and so that through patient organisations cooperation with research groups is promoted.

The European DRIVE project aims to improve pancreatic islet transplantation therapy for diabetes mellitus. Transplantation of purified insulin-producing pancreatic islets from the donor pancreas can restore strict natural blood sugar control and eliminate the need for daily insulin injections, improving the patient’s quality of life. However, despite their proven efficacy among current treatments for type 1 diabetes in the transplantation therapy of insulin-producing pancreatic islets, there is a need to increase the survival of transplanted islet graft. There are also risks associated with immunosuppressive medication to be taken by islet transplant recipients. These factors limit the use of this therapy to a small percentage of patients with “fragile” type 1 diabetes for whom daily insulin injections are not sufficient to control their diabetes.

DRIVE’s significant contribution to improving the quality of life of a patient with diabetes mellitus is to achieve a better outcome in the management of this disease through the development of technologies to increase the survival rate of islet graft transplanted and waive the need for lifelong immune suppression. DRIVE’s vision is to extend the application of islet transplant therapy to more insulin-dependent diabetic patients (T1D and T2D).

Drive Pannel Diabetes - Nanbiosis
Read More

Marisa González, Scientific Director of Unit 16 of NANBIOSIS, candidate to the Rectorate of the University of Extremadura

Marisa González, Scientific Director of NANBIOSIS Unit 16 Surface Characterization and Calorimetry Unit, runs for elections to the Rectorate of the University of Extremadura, to be held on November 27.

Marisa González, Professor of Applied Physics in the Faculty of Sciences and the Group Leader of  Microbial Adhesion research group of CIBER-BBN at University of Extremadura, she works with implants and materials on contact with body fluids and tissues, such as blood or bones, and the importance of knowing how these surfaces interact with proteins and molecules in the blood, and how they would do it in case of that bacteria could arrive that could cause infections in our organism.

In addition to teaching and research, Marisa has experience in the management of the University of Extremadura, she has been, for example, director of the departments of Physics and Applied Physics. In these sense, although Marisa González already stressed that she would not flag her condiction of woman, the truth is that if she wins she would be the first woman to lead the UEx. In fact, it is the first time that there is a female candidate.

In the picture members of CIBER-BBN and NANBIOSIS for Marisa to the UEX in postive!

 

Read More

CIBER-BBN Annual Conferences in Valladolid 12-13 November

CIBER-BBN Annual Conferences are taking place now in Hotel Felipe IV in Valladolid, 150 scientists in the field of nanotechnology, biomaterials and bioengineeering gather to share their progress during this year, present their projects and seek synergies for collaboration.

The NANBIOSIS Session will take place this afternoon at 16:30, and at 18:30 will take place NANBIOSIS Scientificic Advisory Board meeting

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Read More

Update and improvement of unit 20 of NANBIOSIS

NANBIOSIS, U20. In Vivo Experimental Platform, led by Dr. Simó Schwartz and Dr. Ibane Ibasolo, has been recently updated and improved as a result of its participation in the project FICTS1420-20, selected by the MICINN for co-financing by the FEDER Program in ICTS 2014-2020. 

These update and improvement include: DLS meassurement system, a fluorimeter and a waterbath for specific activity assays. The fine characterization of the size and size distribution of nanoparticles is essential for the right understanding of their in vivo behavior. The incorporation of this service to the U20 allows the determination of the drug/fluorophore loading/activity of the drug delivery systemistered in vivo, a good quality control of compounds and nanoparticles, as well as the study of their stability upon storage.

Read More

Nanomedicine: how to get drugs to the place where they have to act.

At the beginning of June, the Jury of the Rei Jaume I 2018 Awards, formed by Nobel Prize winners, businessmen and scientists, met in Valencia to choose the winners.

Today has taken place the ceremony of delivery of the 30th edition of the awards presided over by King Felipe VI. Among the six winners, in the category of New Technologies was Ramón Martínez Mañez, Scientific Director of the CIBER-BBN and Unit 26 of NANBIOSIS.

Coinciding with its thirtieth anniversary, the Rei Jaume Foundation has produced a series of videos of interviews with the winners. In this video, Ramón Martínez Mañez, Scientific Director of Unit 26 of NANBIOSIS, who has received the Rei Jaume I Award for New Technologies, talks about the two major areas in which he works and other topics such as the recognition of science and the need to recover the talent of researchers who go out of Spain and a better connection between research and the company. Some of his answers are the following:

One of our lines of research is in the field of sensors: systems based on nanotechnology for the detection of substances such as the presence of pathogens that may be harmful to health. The other major area is nanomedicines for the controlled release of drugs, one of the fundamental ideas of nanomedicine is how to get drugs to the place where they have to act.

Recognition in science is obtained if your works are cited, having social recognition is much more difficult.

We are a good country in science but we are a country in the second division in the transfer of science to the companies, it is needed more investment so that the products end up coming to the market or so that more research is done in collaboration with companies in Spain.

It is good to leave Spain, not necessarily to succeed but to see how they work in other places. The problem that exists today is that it is very difficult to return to Spain and this is a pity because there are very well educated and very good people who stay abroad.

Read More

Preclinical Study for Brain Tumor with Novel Contrast Agents for MRI

Ana Paula Candiota and Carles Arús, Scientific Cordinator and Scientific Director of  U25 of NANBIOSIS, NMR: Biomedical Applications I  have participated in the research published by ACS Applied Materials & Interfaces Journal  that include a preclinical study carried for brain Tumor.

Extensive attention has been paid on designing and developing functional imaging contrast agents for providing accurate noninvasive evaluation of pathology in vivo. However, alse-positives or ambiguous imaging and the lack of a robust strategy for simultaneous dual-mode imaging remain to be fully addressed. One effective strategy for improving it is to  design magnetic resonance imaging (MRI) contrast agents (CAs) with intrinsic T1/ T2 dual-mode imaging features. In this joint work from ICN2 and CIBER-BBN members, the development and characterization of nanostructured coordination polymers (NCPs) which exhibit dual mode T1/ T2 MRI contrast behavior is described.

The MR characterization was performed at U25 of NANBIOSIS

Article of reference:

Dual T1/T2 Nanoscale Coordination Polymers as Novel Contrast Agents for MRI: A Preclinical Study for Brain Tumor“. S. Suárez-GarcíaN. Arias-RamosC. FriasA. P. CandiotaC. ArúsJ. LorenzoD. Ruiz-Molina, and F. Novio ACS Applied Materials & Interfaces Article ASAP

DOI: 10.1021/acsami.8b15594.

Read More

NANBIOSIS resarchers in CCMIJU identify biomarkers for bridging the gap between preclinical studies in large animal models and clinical trials

Researchers of NANBIOSIS Units at CCMIJU have publish a very relevant article about the studies on  hematological, biochemical and immunological parameters, as well as magnetic resonance derived cardiac function measurements obtained from a swine myocardial infarction model that allows to predict the severity of myocardial infarction in a clinically relevant animal model providing a  simple, affordable and reliable way that could prove useful in the follow up of myocardial infarction and in the evaluation of new therapeutic strategies in this animal model.

Biochemical and hematological determinations were performed by the ICTS Nanbiosis (Unit 19. Clinical test lab at CCMIJU). Flow cytometry analyses were performed by the ICTS Nanbiosis (Unit 14. Cell therapy at CCMIJU). Blood sampling and maintenance of animals were performed by the ICTS Nanbiosis (Unit 22. Animal housing at CCMIJU). Myocardial infarction induction and Magnetic Resonance studies waere performed by the ICTS Nanbiosis (Unit 21. Experimental operating rooms and Unit 24. Medical imaging at CCMIJU).

Article of reference: “Altered hematological, biochemical and immunological parameters as predictive biomarkers of severity in experimental myocardial infarction” DOI: https://doi.org/10.1016/j.vetimm.2018.10.007

 

Read More

The revolution of nanomedicine by Ramón Martínez Mañez

Ramón Martínez Mañez, Scientific Director of Unit 26 of NANBIOSIS NMR: Biomedical Applications II, will be next Monday, November 5 at 7 pm at the Headquarters of Alicante City (San Fernando, 40), where he will impart the conference “The scientific revolution of Nanomedicine,”

The professor of Inorganic Chemistry of the UA and director of the Nanotechnology laboratory, Javier García Martínez, will present the meeting, organized by the Fundación Premios Rey Jaume I and the UA, with the collaboration of the Valencian Agency and Innovation and the Classroom of Science and the Technology of the University of Alicante.

Ramón Martínez-Máñez, director of the Institute for Research in Molecular Recognition and Technological Development (IDM) and scientific director of the Center for Biomedical Research in Networks in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) has been recently awarded King Jaume I of New Technology 2018. The jury of the King Jaume I awarded for New Technologies valued the “exceptional contributions” by Ramón Martínez-Máñez in the development of nanosensors with application in food technology and medicine, as well as “the high scientific quality and social impact of his work “and, for these reasons, he was awarded this award in June 2018. He is also a scholar of the American Chemical Society and the Royal Spanish Society of Chemistry. He was awarded in 2016 by the latter with the prize for Excellence Research

Related news

Read More

FUNCATH: Prevention of infectious diseases with functionalized catheters awarded by La Marató de TV3

FUNCATH project,  coordinated by scientists of NANOMOL  group, led by Dr. Imma Ratera, has been awarded by Fundació La Marató de TV3 .

NANOMOL is the research group that coordinates NANBIOSIS U6 Biomaterial Processing and Nanostructuring Unit, from ICMAB-CSIC and CIBER-BBN.

Fundació La Marató de TV3 2017 call was dedicated to infectious diseases and awarded 36 projects among the 186 evaluated according to their excellence, methodology and relevance.

FUNCATH is the project for Prevention of infections related to vascular catheters by functionalizing catheters impregnated with thermically activatable hydrogels with broad spectrum antimicrobial agents, whose ultimate goal is the development of vascular catheters coated with multibiofunctional hydrogels with broad spectrum antimicrobial activity. The hydrogels will have two functions: first act as a 3D matrix that will support the active biomolecules, specifically cationic peptides (PC), with bactericidal activity against most of the bacteria involved in nosocomial infections and second will act as a protection against the degradation of the PCs until the medical device is used. The latter will be possible thanks to the thermosensitive nature of the hydrogel that will only expose the PCs after their contact with body temperature; which will activate the degradation of the hydrogel and allow the release of active biomolecules. Besides Nanomol group the project involves researchers from the Parc Taulí Hospital, the Hospital Clínic, and the IRTA. The project financing: € 375,078.75 for three years.

 

Read More

NANBIOSIS at the Assembly of Materplat

Next November 14 the General Assembly of Materplat 2018 will take place  in the facilities of the Institute of Ceramics and Glass of the CSIC (ICV-CSIC), on the campus of the Autonomous University of Madrid (Cantoblanco, Madrid).

This year, the theme of the Assembly will be focused on how innovation in materials that can be useful in different fields related to smart cities. In this sense, different speakers will show developments in materials very important for sectors such as health, among others. NANBIOSIS will be present through José Becerra, Professor of Cell Biology at the University of Málaga, Scientific Director of the U28 of NANBIOSIS who will talk about the Customization of Implants and their biological function.

The main novelty of  this year is that the Assembly of MATERPLAT will be a joint day with SAMPE Iberica, the Society for the Advancement of Materials and Process Engineering. This section of the Assembly will feature already confirmed presentations by Fokker / GKN and ARIANE Group.

MATERPLAT is the ADVANCED MATERIALS AND NANOMATERIALS SPANISH TECHNOLOGICAL PLATFORM, whose main goal  is to foster and promote Innovation within the R&D&I National System, as a tool and a key instrument to improve and increase the competitivity of the Spanish companies, for which materials and nanomaterials, along with their  transformation processes, are fundamental elements in the development and commercialization of their products and services. NANBIOSIS participates in Materplat through his Coordinator, Jesus Izco, who leads the Materplat Health Innovation Group

Related news 

Read More